IL140848A - Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate - Google Patents

Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate

Info

Publication number
IL140848A
IL140848A IL14084899A IL14084899A IL140848A IL 140848 A IL140848 A IL 140848A IL 14084899 A IL14084899 A IL 14084899A IL 14084899 A IL14084899 A IL 14084899A IL 140848 A IL140848 A IL 140848A
Authority
IL
Israel
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
pharmaceutical compositions
pharmaceutical composition
Prior art date
Application number
IL14084899A
Other languages
English (en)
Other versions
IL140848A0 (en
Original Assignee
Burzynski Stanislaw R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burzynski Stanislaw R filed Critical Burzynski Stanislaw R
Publication of IL140848A0 publication Critical patent/IL140848A0/xx
Publication of IL140848A publication Critical patent/IL140848A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
IL14084899A 1998-07-23 1999-07-02 Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate IL140848A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (2)

Publication Number Publication Date
IL140848A0 IL140848A0 (en) 2002-02-10
IL140848A true IL140848A (en) 2005-05-17

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14084899A IL140848A (en) 1998-07-23 1999-07-02 Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate

Country Status (21)

Country Link
US (2) US6258849B1 (pl)
EP (1) EP1098643B1 (pl)
JP (2) JP2002521329A (pl)
KR (4) KR100414587B1 (pl)
CN (3) CN100400039C (pl)
AT (1) ATE257378T1 (pl)
AU (1) AU759278B2 (pl)
BR (1) BR9912356A (pl)
CA (1) CA2336945C (pl)
DE (1) DE69914084T2 (pl)
DK (1) DK1098643T3 (pl)
EA (1) EA004179B1 (pl)
ES (1) ES2214866T3 (pl)
HK (1) HK1037142A1 (pl)
ID (1) ID28160A (pl)
IL (1) IL140848A (pl)
NZ (1) NZ509244A (pl)
PL (1) PL213698B1 (pl)
PT (1) PT1098643E (pl)
WO (1) WO2000004894A2 (pl)
ZA (1) ZA200100622B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DE60140491D1 (de) 2000-08-29 2009-12-24 Biocon Ltd Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
DE602005019319D1 (de) 2004-11-26 2010-03-25 Ucl Business Plc Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CA2998344C (en) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
WO2012048043A1 (en) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
MX2017006685A (es) 2014-11-24 2018-01-15 Ucl Business Plc Tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas usando terapias reductoras de amoniaco.
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
CN108369223B (zh) * 2015-12-30 2021-07-06 雀巢产品有限公司 用于测定去脂体重的方法
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
WO2018231733A1 (en) * 2017-06-12 2018-12-20 Burzynski Stanislaw R Methods for the treatment of leptomeningeal disease
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472A (zh) * 2022-12-14 2023-07-28 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
DE69914084D1 (de) 2004-02-12
CN100400039C (zh) 2008-07-09
IL140848A0 (en) 2002-02-10
KR20030027089A (ko) 2003-04-03
CN1660061A (zh) 2005-08-31
ZA200100622B (en) 2002-06-26
AU4854299A (en) 2000-02-14
CN1605334A (zh) 2005-04-13
JP2002521329A (ja) 2002-07-16
EP1098643A2 (en) 2001-05-16
CA2336945C (en) 2008-11-18
US20010044466A1 (en) 2001-11-22
KR100417100B1 (ko) 2004-02-05
EP1098643B1 (en) 2004-01-07
ES2214866T3 (es) 2004-09-16
US6258849B1 (en) 2001-07-10
ID28160A (id) 2001-05-10
EA200100168A1 (ru) 2001-08-27
WO2000004894A2 (en) 2000-02-03
NZ509244A (en) 2004-02-27
WO2000004894A3 (en) 2000-04-27
KR100417101B1 (ko) 2004-02-05
ATE257378T1 (de) 2004-01-15
EA004179B1 (ru) 2004-02-26
DK1098643T3 (da) 2004-05-24
BR9912356A (pt) 2001-04-17
PL345959A1 (en) 2002-01-14
DE69914084T2 (de) 2004-10-28
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
US6943192B2 (en) 2005-09-13
AU759278B2 (en) 2003-04-10
HK1037142A1 (en) 2002-02-01
CA2336945A1 (en) 2000-02-03
PT1098643E (pt) 2004-05-31
KR20030027088A (ko) 2003-04-03
KR20030027087A (ko) 2003-04-03
KR100414587B1 (ko) 2004-01-13
CN1319010A (zh) 2001-10-24
JP2011051993A (ja) 2011-03-17
PL213698B1 (pl) 2013-04-30
CN1191064C (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
IL140848A (en) Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
UA26343C2 (uk) Спосіб одержаhhя коhсервоваhого, що містить протеїh людиhи, лікарського засобу для іh'єкційhого або іhфузійhого введеhhя
ATE390414T1 (de) Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
NO20054324L (no) Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
RO116342B1 (ro) Compoziţie farmaceutică lichidă, orală
AU1537095A (en) Therapeutic agents containing thyroid hormones
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
YU54499A (sh) Farmaceutski preparat za primenu na mukozu
DE60000288T2 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
GEP20012390B (en) Benzonaphthyridines as Bronchial Therapeutics
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
JPS56138110A (en) Suppository containing citric acid or salt thereof
JPS54105221A (en) Preparation of stable concentrated dopa injection
KR900017599A (ko) 종양 치료용 약학 조성물
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
MX9703839A (es) Soluciones intravenosas de lubeluzol.
RO102780B1 (ro) Metoda de anestezie generala
UA30393A (uk) Спосіб лікування коронарного атеросклерозу
JPS5524150A (en) Anti-malignant-tumor agent
JPS5569510A (en) Carcinostatic agent

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired